紫锥菊提取物(Echinacea purpurea extract) - 在研适应症：普通感冒_专利_临床

概要

基本信息

药物类型

中药

别名

Echinacea purpurea alcoholic extract

靶点-

作用方式-

作用机制-

治疗领域

感染呼吸系统疾病

在研适应症

普通感冒

非在研适应症-

原研机构

Laboratoires Arkopharma SA

在研机构

Laboratoires Arkopharma SA

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

16

项与紫锥菊提取物相关的临床试验

CTRI/2022/06/042972

/ Not yet recruiting临床3期IIT

A Comparative Study To Assess The Effectiveness Of Application Of Echinacea Angustifolia Mother Tincture Internally Vis-A-Vis Externally In Cases Of Acne

开始日期2022-06-05

申办/合作机构-

NCT04981314

/ Unknown status临床4期IIT

Study on the Effect of an Echinacea Formulation on the Clinical Manifestations and Evolution of Covid-19

The main objectives of ECCO-2 are: 1) Efficacy: to study whether EQUINACEA ARKOPHARMA, hard caplets containing cryogenized root of the plant Echinacea purpurea, show an improvement of the clinical manifestations and disease course in ambulatory patients with covid-19 with a respiratory presentation and not requiring hospitalization (i.e., mild covid-19). The drug being evaluated will be added as a supplement of the standard treatment, with its current recommended dose for treatment of the common cold. 2) Safety: to determine that the incidence of adverse events is not higher than that seen with the standard treatment applied in each case.

开始日期2021-06-18

申办/合作机构

University of Santiago de Compostela

[+3]

NCT05002179

/ Completed临床4期

Open, Controlled Prospective, Explorative Clinical Trial to Assess Pharmacology and Effectiveness of Echinaforce Chewable Tablets "EC" to Prevent From Enveloped Virus Infections

It is a single-center, randomized, open-label, phase IV study for the explorative investigation of the pharmacological mode-of-action of Echinaforce® extract in the form of Echinaforce® Chewable tablets"- Further, it is aimed to evaluate the effectiveness of the study product for the prevention and treatment of respiratory tract infections in generally healthy adults following a real-life setting. The study covers 2x2 + 1 month of prevention in 120 randomized participants following a tight sampling set-up for sensitive detection of viral infections by RT-qPCR analysis of nasal swabs and seroconversion of SARS-CoV2 IgG/IgM in serum samples.

开始日期2020-11-20

申办/合作机构

A. Vogel AG

[+3]

100 项与紫锥菊提取物相关的临床结果

登录后查看更多信息

100 项与紫锥菊提取物相关的转化医学

登录后查看更多信息

100 项与紫锥菊提取物相关的专利（医药）

登录后查看更多信息

265

项与紫锥菊提取物相关的文献（医药）

2025-05-01·Naunyn-Schmiedeberg's Archives of Pharmacology

Critical analysis of Echinacea preparations marketed in Germany

Article

作者: Seifert, Roland ; Groß, Carina

AbstractColds are the most common cause of incapacity to work in 2023 and therefore have a significant impact on the German economy. Echinacea preparations are considered a non-specific immune stimulant that is used as a phytotherapeutic agent for the treatment and prevention of colds. In the 2021 ZEIT ranking of the best-selling pharmacy-only medicines in Germany, four Echinacea preparations were among the top ten, and they experienced a new hype during the SARS-CoV-2 pandemic. In this study, 22 Echinacea monopreparations, which are approved as herbal medicinal products, were analyzed based on their package inserts. The preparations used in clinical studies were compared with the preparations available on the market with regard to the criteria of plant species used, plant part used, preparation (extract or pressed juice), drug-extract ratio, single dose administered, standardization of the preparations, prior performance of an ingredient analysis, galenics, dosage, duration of administration, and daily dose administered. The analysis revealed that the preparations available on the market are very heterogeneous. The composition can vary considerably in terms of ingredients. For customers, these products appear homogeneous in terms of their presentation on the market. The legal framework conditions promote this situation. The clinical studies are also unable to adequately reflect the market situation. New studies based on market reality, with an analysis of ingredients in the preparations used, a standardized study design, and the inclusion of hematological and biochemical parameters in the evaluation should improve this situation. Days of incapacity for work as an outcome parameter could be well suited.

2025-02-01·The Journal of Pediatric Pharmacology and Therapeutics

The Use and Safety of Cough and Cold Medications in the Pediatric Population

Article

作者: Summerlin, Jenna ; Eiland, Lea S.

Children often experience viral illnesses causing respiratory symptoms. Frequently, nonprescription medications are used in an attempt to decrease the severity and frequency of cough and cold symptoms. Cough and cold medications (CCMs) are not appropriate for all age groups and can have serious adverse effects, including death, especially when used incorrectly. Data surrounding the safety and efficacy of CCMs in patients younger than 6 years are lacking. Currently, the US Food and Drug Administration (FDA) does not recommend the use of cough and cold products that contain an antihistamine or decongestant in children younger than 2 years. Other treatments used by patients for cold symptoms include non-pharmacologic therapies or complementary alternative medications (CAMs), such as zinc or echinacea. Given this is a common ailment for pediatric patients, pharmacists should be knowledgeable about the risks and benefits of each of these therapies to make safe recommendations for patients and their families. This review discusses various cough and cold therapies and the recommendations for their use in pediatric patients.

2025-01-01·Revue Médicale Suisse

Médecine intégrative : ce qui a changé en 2024

Review

作者: Schlaeppi, Marc ; Fleury, Mapi ; Ungarelli-McEvoy, Caitriona ; Berna, Chantal ; Fernandez, Aurore ; Ogal, Mercedes ; Zurron, Noëmi

This article reports on new findings on integrative and complementary medicine published in 2024. The implementation of guidelines for the management of pain in cancer patients is discussed. Then, a literature review is presented, that aims to clarify the role of complementary approaches in the management of chemotherapy-induced nausea and vomiting and provides a concrete example of how recommendations are established. Finally, a meta-analysis focusing on the efficacy of Echinacea in the treatment of upper respiratory tract infections is summarized. These articles illustrate the complexity of the path from science to practice and underscore the importance of identifiable centers of reference to support the dissemination of knowledge to health care professionals and promote broad patient access to well-coordinated therapies.

1

项与紫锥菊提取物相关的新闻（医药）

2021-01-26

·BioSpace

New laboratory (in-vitro) study provides coronavirus insight: A.Vogel's Echinaforce demonstrates anti-viral activity against SARS CoV-2, the virus that causes Covid-19.

MONTREAL, Jan. 26, 2021 /CNW/ - An article titled "In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2" was recently published in the renowned Virology Journal. The study was carried out by researchers of the Spiez laboratory in Switzerland. According to the laboratory (in-vitro) study, A.Vogel's Echinaforce was shown to be effective against coronaviruses in cell experiments, including the SARS-CoV-2 which is commonly known as COVID-19. Despite the promising results, the extent to which the results of the cell experiment can be transferred to humans is still unknown. While authors conclude that 'Echinaforce, could be effective as preventative treatment for all CoVs due to their structural similarities',* these results have yet to be confirmed in human clinical trials. Further scientific studies must be performed to support the preliminary assessment. We are continuing our research in this field on a large scale (human) controlled clinical trial and hope to have results as to the effect on humans in the next year. Echinaforce is officially approved by Health Canada for the following: Echinaforce® is clinically shown to help prevent and relieve the symptoms of upper respiratory tract infections (URTI), such as the common cold and the flu. Shortens the duration of URTI. It is also used to support the immune system, especially in times of stress, lack of sleep and for smokers. It can be taken up to 4 months daily for prevention and there are formulations that are approved for children ages 2+ as well as pregnant and nursing women. *This is preliminary research and does not suggest a clinically applicable therapeutic benefit. A.Vogel follows and supports Health Canada guidelines in the battle against COVID-19. About A.Vogel® A.Vogel® is Canada's leading health brand with a wide range of science based natural products. It was founded in Basel, Switzerland in 1923 by Swiss pioneer Alfred Vogel and entered the Canadian market in 1956. A.Vogel's commitment to organic farming methods means the company uses its own carefully selected seeds, knowing the history of each plant and having full traceability. The efficacy of A.Vogel's fresh plant preparations has been proven by over 30 clinical studies. To learn more, visit avogel.ca. Related links: SOURCE A.Vogel

100 项与紫锥菊提取物相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
普通感冒	法国	Laboratoires Arkopharma SA	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00103012 (CTgov)	临床4期	-	47	Ginkgo Biloba+Lopinavir (Influence of Ginkgo Biloba on Lopinavir Disposition)	顧醖製壓簾齋鑰壓蓋積(壓艱衊簾鑰獵夢餘顧獵) = 築鹽築構鏇鹹廠衊範齋壓衊鏇鹹餘獵鹽鏇顧鑰 (鏇襯製醖鹹蓋鹹鏇顧鬱, 襯醖齋壓廠構網鏇簾壓 ~ 鬱衊顧夢簾簾齋簾齋願)	-	2012-04-16
				Lopinavir (Influence of Echinacea on Lopinavir Disposition)	顧醖製壓簾齋鑰壓蓋積(壓艱衊簾鑰獵夢餘顧獵) = 鹽顧鑰襯糧膚鹹膚憲壓壓衊鏇鹹餘獵鹽鏇顧鑰 (鏇襯製醖鹹蓋鹹鏇顧鬱, 襯壓範顧餘鏇繭蓋艱醖 ~ 鹽淵廠築鹽網衊顧簾糧)